403 related articles for article (PubMed ID: 32000721)
21. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
22. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
Olivier M; Bouaoun L; Villar S; Robitaille A; Cahais V; Heguy A; Byrnes G; Le Calvez-Kelm F; Torres-Mejía G; Alvarado-Cabrero I; Imani-Razavi FS; Inés Sánchez G; Jaramillo R; Porras C; Rodriguez AC; Garmendia ML; Soto JL; Romieu I; Porter P; Guenthoer J; Rinaldi S;
PLoS One; 2019; 14(1):e0210372. PubMed ID: 30653559
[TBL] [Abstract][Full Text] [Related]
23. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
24. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies.
Elshazli RM; Toraih EA; Elgaml A; Kandil E; Fawzy MS
Gene; 2020 Apr; 734():144391. PubMed ID: 32001373
[TBL] [Abstract][Full Text] [Related]
26.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
27. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
29. Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
Aceto GM; Awadelkarim KD; Di Nicola M; Moscatello C; Pantalone MR; Verginelli F; Elwali NE; Mariani-Costantini R
Breast Cancer Res Treat; 2019 Jun; 175(2):479-485. PubMed ID: 30796655
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.
Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
Mol Biol Rep; 2013 Nov; 40(11):6107-12. PubMed ID: 24078161
[TBL] [Abstract][Full Text] [Related]
31. Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients.
De Silva S; Tennekoon KH; Dissanayake A; De Silva K; Jayasekara L
Fam Cancer; 2017 Jul; 16(3):329-338. PubMed ID: 28039656
[TBL] [Abstract][Full Text] [Related]
32. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.
Khan SA; Idrees K; Forslund A; Zeng Z; Rosenberg S; Pincas H; Barany F; Offit K; Laquaglia MP; Paty PB
J Surg Oncol; 2008 Jun; 97(7):621-5. PubMed ID: 18381604
[TBL] [Abstract][Full Text] [Related]
33. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.
Proestling K; Hebar A; Pruckner N; Marton E; Vinatzer U; Schreiber M
PLoS One; 2012; 7(10):e47325. PubMed ID: 23071787
[TBL] [Abstract][Full Text] [Related]
34. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
35. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
37. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
[TBL] [Abstract][Full Text] [Related]
38. Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.
De Oliveira LP; López I; Dos Santos EM; Tucci P; Marín M; Soares FA; Rossi BM; Coudry Rde A
Oncol Rep; 2014 Mar; 31(3):1396-406. PubMed ID: 24366026
[TBL] [Abstract][Full Text] [Related]
39. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
